search Search
search Search

Media Releases

    • Ypsomed and CamDiab expand availability of CamAPS FX on iOS

    Strong momentum following initial launch

    Following its successful pilot launch in March 2025 in Sweden, the iOS app was rolled out in May across Austria, Denmark, Finland, Germany, Ireland, Luxembourg, Norway, Switzerland, and the United Kingdom. The overwhelmingly positive feedback from users in these markets has laid the groundwork for further expansion. As of today, myLoop on iOS is also available in Australia, Belgium, Czechia, France, Italy, the Netherlands, New Zealand, Poland, and Spain.

    ‘‘Our goal is to simplify life for people with diabetes. The very positive feedback on our integrated, intuitive AID system, myLoop, shows that it is truly making a difference, ’’

    explains Sébastien Delarive, Chief Executive Officer of mylife Diabetes Care

    ‘‘Professor Roman Hovorka, Director CamDiab and Professor of Metabolic Technology at the Institute of Metabolic Science and Department of Paediatrics at the University of Cambridge, says: “We are thrilled to bring the CamAPS FX app to iOS users across Europe and beyond. This launch marks a major step in making advanced, adaptive diabetes technology more accessible and convenient.’’

    Seamless integration with leading CGM sensors

    CamAPS FX on iOS is now fully compatible with Continuous Glucose Monitoring (CGM) sensors including the FreeStyle Libre 3 and FreeStyle Libre 3 Plus from Abbott, and the Dexcom G6. This ensures that users can benefit from reliable, real-time glucose data using their preferred CGM device.

    Enhanced data sharing via myInsight+

    Coinciding with this rollout, the myInsight+ data sharing function is now available via the CamAPS FX app in all countries for all operating systems. This feature enables secure sharing of therapy and glucose data with healthcare professionals and caregivers, enhancing support and remote diabetes management.

    Go back